Olverembatinib inhibits SARS‐CoV‐2‐Omicron variant‐mediated cytokine release in human peripheral blood mononuclear cells
Main Authors: | Marina Chan, Eric C Holland, Taranjit S Gujral |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2022-06-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.202215919 |
Similar Items
-
Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia
by: Jianghua Ding, et al.
Published: (2023-11-01) -
A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia
by: Honglan Qian, et al.
Published: (2022-12-01) -
The Difference in Wave Dynamics between SARS-CoV-2 Pre-Omicron and Omicron Variant Waves
by: Franz Konstantin Fuss, et al.
Published: (2022-12-01) -
The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
by: Prerna Arora, et al.
Published: (2022-11-01) -
SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development
by: Danyi Ao, et al.
Published: (2022-03-01)